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Bleeding from oesophageal varices is the most serious 
complication of portal hypertension and accounts for most 
cirrhosis-related deaths.1 A quarter of high-risk cirrhotic 
patients with liver decompensation who present with a first 
major variceal bleed die as a consequence of the bleed.2 
After control of the index bleed, there is a 70% chance 
of rebleeding with a similar mortality if further effective 
treatment is not given.3 Mortality is related to several 
factors, including failure of rapid control of initial bleeding, 
early rebleeding, presence and severity of underlying liver 
disease and functional hepatic reserve.4 Optimal emergency 
management requires an efficient and organised team to 
provide accurate initial assessment of the patient, effective 
resuscitation, rapid endoscopic diagnosis, successful 
intervention with control of bleeding, and prevention of 
early rebleeding as well as the anticipated complications 
of liver decompensation including spontaneous bacterial 
peritonitis, progressive liver and renal failure and hepatic 
encephalopathy.5 The modern management of acute, 
persistent variceal bleeding is therefore best accomplished 
by a skilled, knowledgeable and well-equipped team that can 
offer the full spectrum of treatment options.6
The treatment of variceal haemorrhage has evolved 
markedly in the past decade.4,7 Substantive advances in 
the control of acute variceal bleeding have included new 
and effective drugs,8 improved endoscopic tools and 
techniques and refinements in variceal ligation equipment.9,10 
The selective use of radiologically inserted transjugular 
intrahepatic portosystemic shunts as salvage intervention 
for intractable bleeding,11,12 a diminishing role of narrow-
diameter polytetrafluoroethylene interposition portacaval 
shunts13 and the exponentially increasing demand for 
liver transplantation14 in patients with progressive hepatic 
decompensation and intractable variceal bleeding have 
further improved survival. Despite these advances in 
treatment, uncontrolled or recurrent bleeding from varices 
and the consequences of progressive liver failure remain 
the commonest causes of early death in cirrhotic patients,15 
emphasising the need for medical staff to act swiftly and 
decisively as soon as the patient reaches hospital.16
Several important clinical considerations influence the 
choice of therapy as well as the prognosis in individual 
patients. These include the natural history of the disease 
causing the portal hypertension, location and extent of 
the bleeding varices, residual hepatic function, presence 
of associated systemic disease, continuing alcohol abuse, 
patency of major splanchnic veins and response to each 
specific treatment.4 The natural history of cirrhosis is 
dependent on the degree of functional liver decompensation, 
the magnitude of variceal bleeding and the presence of 
additional complications such as ascites, spontaneous 
bacterial peritonitis, portal vein thrombosis or hepatocellular 
carcinoma.17 Progressive liver decompensation occurs 
more rapidly in patients with alcoholic cirrhosis than in 
those with cirrhosis caused by viral hepatitis B or C and 
is often associated with super-added alcoholic hepatitis. 
Once decompensation occurs in cirrhotic patients, mortality 
without organ replacement is as high as 85% over 5 years.18 
Defining prognosis is an essential part of the assessment 
of cirrhosis and forms the basis of any future treatment 
decisions.19 
The spectrum of interventions required to control recurrent 
variceal bleeding and achieve efficient and successful 
treatment of the severe and potentially life-threatening 
complications of portal hypertension have become 
increasingly invasive, resource-dependent and sophisticated 
and often require advanced specialist skills.20 Selection of the 
appropriate intervention is critical as the rational treatment 
of oesophageal varices requires a full appreciation of the 
haemodynamic consequences of variceal bleeding and a clear 
understanding of the risks of rebleeding and the response 
to each specific intervention.21 The ideal treatment of portal 
hypertension and bleeding varices should be universally 
effective, safe, easy to administer and inexpensive. As no 
such panacea exists, and no single treatment is applicable 
to all patients, knowledge of the alternatives allows the 
well-informed surgeon, gastro-enterologist, hepatologist or 
intensivist to choose the appropriate therapy for each clinical 
situation.
The advent of modern endoscopic therapy has moved 
the endoscopist to centre stage in the initial management 
of variceal bleeding.22 Because diagnostic endoscopy is key 
to the confirmation of bleeding varices, the endoscopist’s 
role as gatekeeper is pivotal in variceal management.23 
Sustained control of acute bleeding is critical for survival 
because marginal liver function worsens inexorably with 
each subsequent major bleed.7 An analysis of the incidence 
of death due to uncontrolled variceal bleeding in 8 combined 
studies involving 1 488 patients reported an 8% mortality for 
exsanguination within 48 hours of admission to hospital,24 
while in another survey death due to uncontrolled bleeding 
occurred in 6.2% of patients.15 Even when initial control of 
variceal bleeding is successful, there is a significant chance of 
rebleeding. Early rebleeding is a strong predictor of mortality 
and recurrent variceal bleeding substantially increases the 
risk of complications which further contribute to mortality,24 
emphasising that rapid and lasting control of variceal 
bleeding remains the principal imperative of endoscopic 
intervention.7
The extent and urgency of initial therapy for variceal 
bleeding depends on the magnitude and severity of the 
bleeding episode.4 Establishment and maintenance of a 
secure airway, and prompt resuscitation with restoration of 
circulating blood volume, are vital and precede any diagnostic 
studies.5 Both intravenous and central venous access may be 
necessary, the latter preferably after correction of existing 
coagulopathy. While blood is being cross-matched, crystalloid 
solution is rapidly infused until the blood pressure is restored 
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and urine output is adequate. Saline infusions may aggravate 
ascites and should be avoided, and overzealous expansion of 
circulating blood volume may cause a rebound increase in 
portal pressure and precipitate further bleeding.15 Patients 
who are haemodynamically unstable, elderly or who have 
cardiac or pulmonary disease should be monitored using a 
pulmonary artery catheter because injudicious administration 
of fluids combined with vaso-active drugs may lead to rapid 
onset of oedema, ascites and hyponatraemia.4 Clotting 
factors are often deficient and fresh blood, fresh-frozen 
plasma and vitamin K1 are frequently required.
5 Platelet 
transfusions may be necessary. Sedatives should be avoided 
to prevent worsening of incipient encephalopathy. All patients 
with cirrhosis and upper gastro-intestinal bleeding should 
receive short-term prophylactic antibiotics to prevent serious 
infectious complications.25
Empirical pharmacological therapy has a critical advantage 
in that special technical expertise for administration 
and monitoring is not required. Most endoscopy units 
recommend that pharmacological therapy be started when 
a diagnosis of variceal bleeding is suspected and before 
emergency endoscopy is performed.25 This policy has the 
theoretical advantage of controlling bleeding before the initial 
endoscopy, which makes both diagnosis and immediate 
endoscopic therapy easier. The selection of vaso-active 
therapy depends on local resources. Glypressin (terlipressin), 
the synthetic analogue of vasopressin, is the vasoconstrictor 
of choice, with few side-effects and the added advantage of 
being effective in 2 mg intravenous bolus doses administered 
4-hourly, simplifying administration. Early administration 
of glypressin has shown to improve survival.25 Somatostatin 
and its synthetic analogues, octreotide and vapreotide, stop 
variceal bleeding in up to 80% of patients, and because of 
their excellent safety profile can be used without special 
monitoring. Beta-blockade is ineffective and contraindicated 
in patients who are actively bleeding and are shocked.25
Variceal band ligation is as effective as injection 
sclerotherapy and is the endoscopic intervention of choice 
both for acute variceal bleeding and long-term variceal 
eradication therapy.9 Most endoscopists prefer immediate 
intervention during the diagnostic endoscopy with application 
of bands at and above the bleeding site. Balloon tamponade is 
a useful temporary bridge in the case of massive uncontrolled 
or recurrent bleeding. Continued life-threatening variceal 
bleeding after two endoscopic procedures requires escalation 
of therapy.1 The introduction of minimally invasive, 
radiologically placed transjugular intrahepatic portosystemic 
shunts (TIPS) is a valuable rescue therapy for patients with 
uncontrolled or refractory variceal bleeding unresponsive 
to standard pharmacological and endoscopic therapy. TIPS 
placement has a mortality rate of less than 1% and morbidity 
rates less than 10% in skilled hands in selected patients. The 
major disadvantages after TIPS are stent dysfunction and 
hepatic encephalopathy.2,13 
All patients are at high risk for rebleeding after control 
of the first variceal bleed. Either endoscopic variceal band 
ligation or pharmacological treatment with β-adrenergic 
blockers is an accepted first-line therapy to prevent variceal 
rebleeding. Non-selective, i.e. blocking both β-1 cardiac 
and β-2 vascular receptors, β-adrenergic blockers should 
be used.8 The major disadvantages of β-adrenergic blockers 
in clinical practice are the substantial number of cirrhotic 
patients (up to 20%) who have contraindications precluding 
the use of β-blockers and an additional 5% of patients who 
develop intolerance to treatment that results in withdrawal of 
the medication. A further significant disadvantage is that only 
40% of patients receiving long-term β-blockers achieve the 
desired therapeutic reduction in portal pressure of 20% from 
baseline or to levels less than 12 mmHg.26 Failure to achieve 
these haemodynamic targets is the strongest independent 
predictor of variceal rebleeding.26 More recently, β-blockers 
in combination with isosorbide mononitrates, which enhance 
the reduction in portal pressure, have been used. 
Several studies have sought to identify prognostic 
indicators associated with early variceal rebleeding. 
Multivariate analyses have demonstrated that active bleeding 
at emergency endoscopy,27-31 variceal size,32 Child-Pugh 
grade,27,30-34 Child-Pugh score,28,30,35,36 haematocrit levels,27,35 
bacterial infection,30,35,37,38 encephalopathy,28 portal vein 
thrombosis,27 platelet count,28 hepatocellular carcinoma,32,35 
continued alcohol abuse,28,32,35 hypo-albuminaemia30 and a 
hepatic venous pressure gradient >20 mmHg35,39-42 measured 
shortly after admission have been identified as independent 
prognostic factors for early rebleeding30 and significant 
predictors of risk for 5-day failure to control bleeding.40,43 
However, the conclusions in these studies are often 
discordant and the predictive value of the results difficult to 
assess from the data. Differences in these studies include an 
absence of rigorous endoscopic criteria for defining variceal 
rebleeding, lack of standardisation of time of entry and wide 
differences in patient sampling (percentage of alcoholics, 
percentage of Child-Pugh grade of patients, active bleeding 
at endoscopy) which question the validity of these data and 
the relevance and applicability to other population groups. 
There is a wide variation in the reported mortality rates 
after the first episode of variceal bleeding related in particular 
to differences in the interpretation of time ‘zero’ and the 
inclusion of patients beyond the first 48 hours of onset of 
initial bleeding. In addition, some studies include patients 
who have had a first bleed as well as patients who present 
with subsequent variceal bleeds. In these selected groups, 
mortality rates differ markedly. Published studies also include 
widely differing proportions of alcoholic and Child-Pugh 
grade C patients.44 The most frequently reported predictive 
factors associated with an increased mortality at 6 weeks are 
active bleeding at endoscopy,45 variceal size,46 hypovolaemic 
shock,33,47,48 units of blood transfused,49 early rebleeding,28,33,50 
Child-Pugh grade,33,34,51-53 model for end-stage liver disease 
(MELD) score >15,54 HVPG >20 mmHg,47 renal failure,47,55 
blood urea or creatinine,28,35,56-59 total bilirubin,57,59,60 
international normalised ratio (INR),49,56,57 ascites,60 hepatic 
encephalopathy,28,49,56,61 albumin,52,62 bacterial infection,53 
hepatocellular carcinoma,46,47,54,59,60 continued alcohol abuse46 
and age.48,61 Unfortunately the consistency of these results 
is variable and conflicting because of small sample sizes, 
potential referral bias, dissimilar study end-points, differences 
in patient selection, causes of cirrhosis and techniques of 
endoscopic intervention and they have not found general 
utility in current portal hypertensive literature.
Several studies have attempted to develop a classification 
that can both characterise the degree of liver injury and 
predict the prognosis of patients with cirrhosis on the basis 
of clinical and laboratory variables.18 Because of its simplicity 
and ease of use, the Child-Pugh classification has been 
widely used to predict survival in cirrhotic patients and the 
development of complications such as variceal bleeding and 
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response to surgical intervention.63 The major limitations 
in the Child-Pugh classification are lack of inter-observer 
concordance and clinical subjectivity in assessing the degree 
of ascites and encephalopathy and the poor discrimination in 
patients with Child-Pugh scores between 10 and 15 in class 
C. The MELD score, which was originally designed to assess 
the prognosis of cirrhotic patients having a transjugular 
intrahepatic portosystemic shunt, is a continuous score 
relying on three objective variables.64 MELD has replaced 
the Child-Pugh score in Europe and the USA for prioritising 
liver donor allocation according to a ‘sickest first’ policy.15 
MELD is based on creatinine, bilirubin, and the INR and 
is considered more reproducible because the components 
do not include subjective variables such as ascites and 
encephalopathy.64 However, both the Child-Pugh and MELD 
scores can vary substantially if single variables are modified 
by medical treatment such as an albumin infusion, ascitic 
paracentesis, or over-zealous diuretic therapy, which can 
increase serum creatinine. MELD best predicts 3-month 
survival of cirrhotic patients, irrespective of cause. In studies 
by Bambha et al.,65 Chalasani et al.58 and Amitrano et al.54 
MELD was a clinically useful and objective predictor of 
short-term survival after acute variceal bleeding. However, 
current interest in prognostic scoring in acute variceal 
bleeding continues to evolve, and modified versions of 
both the original Child-Pugh and MELD scores are now 
available.66
Substantial progress in the treatment of variceal bleeding 
has occurred since the review ‘Taking the tension out of the 
portal system’ by the Kings College Liver Group.67 However, 
despite the plethora of randomised controlled trials in portal 
hypertensive bleeding, there is considerable variation in 
the quality of studies with regard to selection, assessment 
and attrition bias, with consequent deficiencies leaving 
unanswered questions. Understanding the problems inherent 
in the design, execution and interpretation of clinical trials 
in portal hypertension is critical in deciding whether the 
results apply to the care of a specific patient.22 For example, 
when assessing endoscopic control of bleeding and survival 
in patients with varices, trials with a large proportion of 
alcoholic patients who have advanced cirrhosis and liver 
decompensation are less likely to show a difference in 
bleeding control as death from recurrent bleeding is replaced 
by early death from liver failure in a high-risk population.22 
The implications for future research into portal hypertension 
are that adequately powered, adequately conducted, properly 
reported multicentre trials need to continue to address 
unresolved issues. As patient trial recruitment becomes an 
increasing impediment, future studies will require uniform 
and internationally accepted protocols to facilitate aggregate 
analyses and future meta-analyses. In addition, the ever-
increasing demand for medical fiscal discipline and logistic 
efficiency requires that cost factors be adequately addressed 
in prospective studies. These issues have been raised at 
the Baveno Consensus Conferences.47,68-70 Identification 
and knowledge of accurate prognostic factors predicting 
early rebleeding should ideally provide a powerful tool to 
identify at an early stage those patients in whom conventional 
treatment is likely to be unsuccessful and who require urgent 
implementation of an aggressive salvage strategy. Future 
prospective studies incorporating and evaluating the full 
spectrum of prognostic factors including clinical variables, 
liver biochemistry, endoscopic intervention, portal pressures 
and comparative MELD and Child-Pugh assessment will 
be valuable advances in improving the effective and rational 
management of patients with bleeding oesophageal varices 
and portal hypertension. 
J. E. J. Krige
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